Approval · Notice of Compliance 28735 · 2022
COSENTYX: Notice of Compliance 28735
Issued August 10, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28735
- Date
- August 10, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Presentation
Products in this notice
Medicinal ingredients
- SECUKINUMAB 300 MG per 2ML
- SECUKINUMAB 300 MG per 0.2ML